“Success within the OTC market can extend the life of an Rx product that has been switched. In order to increase the likelihood that a product is successful post-switch, the manufacturer will often switch to OTC status as the product approaches patent expiry, rather than afterwards.”

The Pharmaceutical OTC Outlook to 2010 by Kate Bradley
Business Insights is a series of management reports designed to help you make informed, timely business decisions. We understand the problems facing today’s managers in taking your business’ into the next millennium, and appreciate the importance of the role of accurate, up-to-date, incisive market and company analysis. We help you to crystallise your business decision making.

Business Insights’ reports are authored by independent experts in their fields and offer results from our unique primary research methodology. Our authors’ leading positions allow them to interview key industry executives and to quantify which issues will be of greatest strategic significance in an industry’s future. The results of our analysis and recommendations will help you to evaluate the impact of these issues on your business, and plan to position yourselves to take the greatest advantage of opportunities which will arise in tomorrow’s commercial environment.

The strength of our Healthcare research and analysis function is derived from its access to unparalleled databases and libraries of information, its proprietary analytic techniques and its people. Staff are drawn from a very wide set of disciplines including strategic consultancy, medicine, the pharmaceutical industry, IT consultancy, accountancy and legal practice. They have a large variety of functional skill bases, from technician to sales and marketing, and collectively speak numerous different European, Asian and other languages.

Trusted by blue chip companies

Our client list includes:

Your guide to success

Factors affecting the growth of the OTC market within different geographic regions

“The switching of ethical drugs to OTC status has been driven primarily by the commercial interests of individual pharmaceutical companies and by the desire of individual governments to curtail the growth of their national drug bills”.

The Pharmaceutical OTC Outlook to 2010

Research methodology

Examples of self-recognised and self-diagnosed conditions which may be treated by Rx to OTC switched products

“Diagnosis is traditionally the domain of physicians, as superior medical knowledge can avoid costly and inaccurate treatment decisions. However, with the increasing availability of test kits and improving public knowledge of health issues, self-diagnosis is becoming more accurate and commonplace”.

The Pharmaceutical OTC Outlook to 2010

This report focuses on the development of the OTC market in terms of the current dynamics and future evolution. Within this framework, detailed analysis of the drivers for growth and the barriers to expansion is conducted, covering pharmaceutical to OTC switches, changes in political climate and the development of OTC industry as a cost containment tool.

The major players in the OTC market are identified and profiled, along with the products that drive these companies. Individual markets are also examined. These include the US, as the leading market in OTC products, Japan, the largest Asian market and the major European markets of Germany, France, Spain, Italy and the UK. The current and potential value of these countries is assessed, as is the potential for expansion into emerging markets.

Detailed forecasts of leading products and companies are also provided, along with predictions for future trends enabling current gaps and future opportunities in OTC medicines to be highlighted.

The Pharmaceutical OTC Outlook to 2010 benefits from over 100 in-depth interviews with senior executives in all the major pharmaceutical and healthcare sectors to ascertain each company’s strategic positioning and future plans, together with their individual view of the marketplace in which they operate:

50 members of national and international nonprescription drug associations

25 US and European marketing executives within the major companies in the OTC market

16 international OTC product/business managers

10 press agencies of the major companies within the OTC market
Structure and scope

### Total savings in US healthcare provision attributable to OTC switched products

<table>
<thead>
<tr>
<th>Category</th>
<th>% of category switched</th>
<th>Total OTC savings ($m)</th>
<th>Savings attributable switched products ($m)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headache, arthritis, and muscle</td>
<td>44.0</td>
<td>6,945</td>
<td>3,056</td>
</tr>
<tr>
<td>Common cold</td>
<td>97.4</td>
<td>3,093</td>
<td>3,013</td>
</tr>
<tr>
<td>Allergy</td>
<td>99.6</td>
<td>2,076</td>
<td>2,064</td>
</tr>
<tr>
<td>Heartburn/Indigestion</td>
<td>58.6</td>
<td>1,337</td>
<td>924</td>
</tr>
<tr>
<td>Sinusitis</td>
<td>100.0</td>
<td>1,067</td>
<td>1,067</td>
</tr>
<tr>
<td>Athlete's foot/itch</td>
<td>69.1</td>
<td>1,337</td>
<td>924</td>
</tr>
<tr>
<td>Rash/itchy skin</td>
<td>54.7</td>
<td>1,167</td>
<td>638</td>
</tr>
<tr>
<td>Vaginal yeast infection</td>
<td>100.0</td>
<td>531</td>
<td>531</td>
</tr>
<tr>
<td>Acne</td>
<td>24.0</td>
<td>741</td>
<td>179</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>20,621</strong></td>
<td><strong>12,885</strong></td>
<td><strong>7,806</strong></td>
</tr>
</tbody>
</table>

Source: Datamonitor, Non-prescription drug manufacturers association

Survey - Datamonitor’s survey identifies the role that the OTC market plays within the healthcare environment and the current and future dynamics of the industry in terms of OTC therapies and individual countries.

Country specific outlines - the current OTC environments of the European community, the US and Japan. The role of OTC within the healthcare systems of these countries in terms of governmental cost containment measures, and consumer and healthcare provider attitudes.

**Key benefits**

- **Identify** potential commercial value
- **Evaluate** what factors influence the OTC market
- **Analyze** the drivers for growth and the barriers to expansion within the global OTC market
- **Assess** the status of the OTC industry within the US, as the leading market in OTC products, Japan, as the largest Asian market and the major European markets
- **Identify** current gaps and future opportunities in the OTC pharmaceuticals market
- **Analyze** the key drivers in the expansion of the OTC market
- **Understand** the role of OTC medication within disease management and cost containment
- **Highlight** how the industry is evolving and which areas provide the most significant opportunities

"Rx-to-OTC switching has been pivotal to the growth of the Japanese OTC market, which is currently the second largest in the world. It has provided the research-based industry within Japan an entry into the self-medication market and an escape from the downwards price spiral in the reimbursed sector".

**The Pharmaceutical OTC Outlook to 2010**

Sales of SmithKline Beecham’s Consumer Healthcare products by sector, 1997

<table>
<thead>
<tr>
<th>Therapeutic area</th>
<th>Major product in portfolio</th>
<th>Sales 1997 ($m)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smoking cessation</td>
<td>Nicorette and Nicoderm CQ</td>
<td>648</td>
</tr>
<tr>
<td>Analgesics</td>
<td>Paracetamol/acetaminofluoride</td>
<td>256</td>
</tr>
<tr>
<td>Dermatological</td>
<td>Tums</td>
<td>177</td>
</tr>
<tr>
<td>Respiratory tract</td>
<td>Contac</td>
<td>100</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>OXY</td>
<td>75</td>
</tr>
<tr>
<td>Vitamins and minerals</td>
<td>Claritin</td>
<td>71</td>
</tr>
<tr>
<td>Sales of other consumer healthcare products</td>
<td></td>
<td>1,767</td>
</tr>
<tr>
<td>Total OTC sales</td>
<td></td>
<td>2,080</td>
</tr>
<tr>
<td>Total Consumer Healthcare sales</td>
<td></td>
<td>3,700</td>
</tr>
</tbody>
</table>

Source: Datamonitor, SmithKline Beecham Annual Report 1997

"...the volatile nature of this (the smoking cessation) market is evidence that consumers regard smoking cessation products as a fad, which may have been reflected by the difficulties companies have encountered in developing brand loyalty"

**The Pharmaceutical OTC Outlook to 2010**
Are Business Insights’ Outlook reports for you?
Examine the Target Index below:

<table>
<thead>
<tr>
<th>Company type</th>
<th>Ethical Manufacturers</th>
<th>OTC Companies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strategic Planning</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Business Development</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Competitive Intelligence</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Product Management</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Sales &amp; Marketing</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Market Research</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Finance</td>
<td>✓</td>
<td>✓</td>
</tr>
</tbody>
</table>

Legal classification of OTC pharmaceuticals in four major markets:

<table>
<thead>
<tr>
<th>Country</th>
<th>Code</th>
<th>Distribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>US</td>
<td>OTC</td>
<td>retail outlets</td>
</tr>
<tr>
<td>UK</td>
<td>P medicines, GSL medicines</td>
<td>pharmacy only, any lockable sales outlet</td>
</tr>
<tr>
<td>Japan</td>
<td>Designed product, OTC</td>
<td>pharmacy and first class drug stores, pharmacy and all drugstores</td>
</tr>
<tr>
<td>France</td>
<td>Grand public, Prescription only</td>
<td>any advertising media, only point-of-sale advertising</td>
</tr>
<tr>
<td>Germany</td>
<td>Pharmaceutical product</td>
<td>non-prescription-bound medicines which may be purchased with or without a prescription, free sale non-prescription-bound medicines for general sale without prescription</td>
</tr>
</tbody>
</table>

“OTC products tend to be categorised according to the method by which they are distributed. In certain countries, such as the US, all OTC products are available from retail outlets over and above pharmacists. However, in the majority of countries there are legal subclasses which can involve some products being restricted to certain distribution outlets”.

“Of the more developed markets (the US, Europe, Japan), it is forecast that Europe will display the strongest growth into the next century. Growth of 7% is predicted between 1998 and 2005, falling to 5% thereafter”.

The Pharmaceutical OTC Outlook to 2010
# EXECUTIVE SUMMARY

Overview of the global OTC Pharmaceutical Market  
The dynamics of the OTC pharmaceutical market  
Country profiles  
Company profiles  
The future of the OTC pharmaceutical market

## CHAPTER 1 INTRODUCTION TO OTC PHARMACEUTICALS

Summary  
Definition of OTC pharmaceuticals  
Historical development of the OTC market  
Historical drivers of the OTC market  
Distribution and retail of OTC pharmaceuticals  
Direct distribution of OTC pharmaceuticals  
Mail order distribution of OTC pharmaceuticals  
Wholesale distribution of OTC pharmaceuticals  
Agency distribution of OTC pharmaceuticals  
Pharmacies as retail outlets for switched drugs  
Growth in the OTC market

## CHAPTER 2 THE DYNAMICS OF THE OTC PHARMACEUTICAL MARKET

Summary  
The current OTC market  
Geographical breakdown of the OTC market  
Emerging markets  
Major players within the OTC market  
Introduction  
Johnson & Johnson  
American Home Products  
Company structure  
SmithKline Beecham  
Warner-Lambert  
Bayer

## CHAPTER 3 CURRENT ACTIVITY IN THE OTC MARKET

Summary  
OTC pharmaceuticals: growth or maturity?  
Growth potential within the OTC market  
Geographical influences on growth potential

## CHAPTER 4 FUTURE DRIVERS OF OTC PHARMACEUTICALS

Summary  
Rx-to-OTC switching  
Pharmaceutical companies protecting profits  
Dual regulatory status  
Geographic expansion  
The changing role of the consumer  
The manufacturers response to consumer empowerment  
New indications  
Anti-infectives  
Asthma  
Anxiety  
Migraine treatments  
Female contraceptives  
Cholesterol lowering agents  
The impact of technology on the OTC market  
Patient management systems  
New marketing channels—the internet  
Information gathering  
Governmental cost containment  
Pharmacists’ drive to extend their role  
Patient empowerment

## CHAPTER 5 FUTURE TRENDS WITHIN THE OTC PHARMACEUTICAL MARKET

Summary  
Future trends in the OTC pharmaceutical industry

## LIST OF FIGURES

<table>
<thead>
<tr>
<th>Figure</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Figure 1.1:</td>
<td>The life cycle of a pharmaceutical product with and without a switch to OTC status</td>
</tr>
<tr>
<td>Figure 1.2:</td>
<td>Contemporary distribution channels for OTC products</td>
</tr>
<tr>
<td>Figure 1.3:</td>
<td>Taisho’s OTC marketing system: a model for direct distribution</td>
</tr>
<tr>
<td>Figure 1.4:</td>
<td>Diversification process in the pharmaceutical retail environment to facilitate organic growth</td>
</tr>
<tr>
<td>Figure 2.6:</td>
<td>The three leading non-prescription products share of Warner-Lambert’s global revenue for Consumer</td>
</tr>
</tbody>
</table>
Figure 2.7: The three leading non-prescription products share of Warner-Lamberts US revenue for Consumer Healthcare products, 1997

Figure 3.8: Factors affecting the growth of the OTC market within different geographic regions

Figure 3.9: Market share of the five leading markets within the total European market for non-prescription pharmaceuticals by value in 1997

Figure 3.10: The 10 major European markets of non-prescription drug medicines by averaged individual spend, 1997

Figure 3.11: The structure of the prescription and non-prescription pharmaceutical market in Germany

Figure 3.12: Percentage growth within the German pharmaceutical market by segment, 1995-96 and 1996-97

Figure 4.13: Factors influencing switching

Figure 4.14: Examples of self-recognised and self-diagnosed conditions for which Rx-to-OTC switched products could be used to alleviate

Figure 5.15: Positioning of OTC pharmaceuticals

Figure 5.16: Evolution of the OTC market

LIST OF TABLES

Table 1.1: Legal classification of OTC pharmaceuticals in four major markets
Table 1.2: OTC retail sales in the US, 1964-1997
Table 2.3: The leading 20 companies in the global OTC market, 1996
Table 2.4: Total and US sales of Consumer Healthcare products, 1997
Table 2.5: Sales of the three leading products and total Consumer Healthcare products in 1997
Table 2.6: US sales of the leading brands of OTC pharmaceuticals, 1997
Table 3.7: The estimated value of the European non-prescription drugs market, 1997
Table 3.8: The 10 major European markets of non-prescription drug medicines by value per person, 1997
Table 3.9: Self-medication share of total pharmaceutical market in a range European countries, 1997
Table 3.10: Prescription and non-prescription sales of pharmaceutical products in Germany, 1996-97
Table 3.11: Total savings in US healthcare provision attributable to Rx-to-OTC switched products
Table 3.12: FDA approvals for OTC smoking cessation products
Table 4.13: Approvals of Rx-to-OTC switches by the food and drug administration, 1994-1998